HC Wainwright Issues Pessimistic Estimate for RVMD Earnings

Revolution Medicines, Inc. (NASDAQ:RVMD) – Stock analysts at HC Wainwright lowered their Q1 2025 earnings per share estimates for shares of Revolution Medicines in a report released on Monday, March 3rd. HC Wainwright analyst R. Burns now anticipates that the company will earn ($1.09) per share for the quarter, down from their previous forecast of ($0.92). HC Wainwright has a “Buy” rating and a $73.00 price objective on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($3.49) per share. HC Wainwright also issued estimates for Revolution Medicines’ Q2 2025 earnings at ($1.12) EPS, Q3 2025 earnings at ($1.14) EPS, Q4 2025 earnings at ($1.17) EPS and FY2025 earnings at ($4.51) EPS.

Revolution Medicines (NASDAQ:RVMD) last issued its earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.11).

Several other brokerages have also weighed in on RVMD. Piper Sandler upped their target price on Revolution Medicines from $57.00 to $70.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Guggenheim upped their target price on Revolution Medicines from $82.00 to $87.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. JPMorgan Chase & Co. upped their price target on Revolution Medicines from $63.00 to $71.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 3rd. UBS Group upped their price target on Revolution Medicines from $65.00 to $71.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Finally, Wedbush reiterated an “outperform” rating and set a $67.00 price target on shares of Revolution Medicines in a research note on Thursday, February 27th. Twelve equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $66.31.

Revolution Medicines Price Performance

Shares of RVMD stock opened at $39.22 on Thursday. Revolution Medicines has a fifty-two week low of $29.55 and a fifty-two week high of $62.40. The stock’s 50-day moving average is $41.69 and its two-hundred day moving average is $46.06. The firm has a market cap of $7.29 billion, a P/E ratio of -10.92 and a beta of 1.46.

Institutional Trading of Revolution Medicines

Several hedge funds have recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB bought a new stake in shares of Revolution Medicines in the 3rd quarter worth approximately $801,000. Citigroup Inc. lifted its position in shares of Revolution Medicines by 29.5% in the 3rd quarter. Citigroup Inc. now owns 117,938 shares of the company’s stock worth $5,348,000 after acquiring an additional 26,871 shares during the period. State Street Corp lifted its position in shares of Revolution Medicines by 4.1% in the 3rd quarter. State Street Corp now owns 5,279,584 shares of the company’s stock worth $239,429,000 after acquiring an additional 208,516 shares during the period. Barclays PLC lifted its position in shares of Revolution Medicines by 187.1% in the 3rd quarter. Barclays PLC now owns 294,664 shares of the company’s stock worth $13,362,000 after acquiring an additional 192,021 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Revolution Medicines by 58.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,763,117 shares of the company’s stock worth $79,957,000 after acquiring an additional 653,433 shares during the period. Institutional investors own 94.34% of the company’s stock.

Insider Activity at Revolution Medicines

In related news, COO Margaret A. Horn sold 4,329 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $45.40, for a total transaction of $196,536.60. Following the completion of the sale, the chief operating officer now owns 127,991 shares in the company, valued at $5,810,791.40. This represents a 3.27 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Jack Anders sold 2,635 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $45.40, for a total value of $119,629.00. Following the sale, the chief financial officer now owns 96,470 shares of the company’s stock, valued at approximately $4,379,738. The trade was a 2.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,678 shares of company stock worth $847,981 in the last 90 days. 8.00% of the stock is owned by company insiders.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.